NCT07105956Not yet recruiting
Radiolabeled TSPO Targeted Molecular Probe in Alzheimer's Disease.
Clinical Application of a Novel Radiolabeled Translocator Protein (TSPO) Targeted Small Molecular Probe in Neuroinflammation Imaging of Alzheimer's Disease.
Source: ClinicalTrials.gov · Last updated 6 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Evaluate the clinical application value of the novel radiolabeled TSPO-targeted molecular probe Gallium \[68Ga\]-DOTA-HK-011 in neuroinflammation imaging of Alzheimer's disease.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 8 (estimated)
- First submitted
- 30 Jul 2025
- Start date
- 1 Sept 2025
- Primary completion date
- 31 Aug 2026
- Lead sponsor
- Nanjing First Hospital, Nanjing Medical University
- Diseases
- Alzheimer disease
- NCT number
- NCT07105956
What you commit to
- Study type: Observational
- Planned participants: 8
- From 1 Sept 2025 to the primary completion date, 31 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of anti-inflammatory drugs, including corticosteroids and immunosuppressants, within the past 14 days, which may interfere with the accuracy of inflammation imaging.
Other illness
- Individuals with a history of allergy to drugs chemically or biologically similar to TSPO, a history of atopy, or currently suffering from allergic diseases.
- Presence of other coexisting neurological diseases, such as stroke, Parkinson's disease, brain tumors, or mental disorders, including depressive disorder and schizophrenia.
- Severe cardiac, pulmonary, hepatic, or renal dysfunction, or uncontrolled systemic diseases; 5. Presence of metal implants contraindicated for MRI, including but not limited to cardiac pacemakers, artificial heart valves, and metal stents.
- Patients whose physical condition is unsuitable for radioactive tracer-based imaging examinations.
Other
- Claustrophobia or inability to tolerate prolonged examinations.
- Pregnant women (defined as those with a positive urine pregnancy test) or breastfeeding women.
- Other circumstances deemed unsuitable for participation in the trial by the researcher.
Who the study is looking for
- Volunteer for the trial, with the patient or their legal guardian signing the informed consent form.
- Volunteers are not limited by gender, and the age range is from 18 to 75 years old, including both ends.
- The patient is diagnosed with Alzheimer's disease (AD), supported by a positive amyloid PET scan.
- The patient has completed Tau PET scan.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nanjing First Hospital Coordinator of this site? Confirm its status | Nanjing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.